Faculty
Steve Oh.jpg

Stephen T. Oh, MD, PhD

Assistant Professor
Department of Medicine
Hematology Division
Department of Pathology & Immunology

Research Interests

  • Myeloproliferative neoplasms

Contact

Peer-reviewed Publications

  • A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis
    Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J
    Br J Haematol 2017 Mar;176(6):939-949
  • Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
    How J, Zhou A, Oh ST
    Ther Adv Hematol 2017 Mar;8(3):107-118
  • Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
    Fisher DA, Malkova O, Engle EK, Miner C, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST
    Leukemia 2016 Dec 23; [Epub ahead of print]
  • TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
    Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H
    J Natl Compr Canc Netw 2016 Dec;14(12):1572-1611
  • Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Clinical improvement with JAK2 inhibition in Chuvash polycythemia
    Zhou AW, Knoche EM, Engle EK, Ban-Hoefen M, Kaiwar C, Oh ST
    N Engl J Med 2016 Aug 4;375(5):494-6
  • Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis
    Rashidi A, Heusel JW, Oh ST
    Blood Cells Mol Dis 2016 Sep;60:1-2
  • Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
    Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
    Blood Cancer J 2015 Oct 2;5:e351
  • Brief report: chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis
    Miner JJ, Aw Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST, Kim AH, Diamond MS, Lenschow DJ, Yokoyama WM
    Arthritis Rheumatol 2015 May;67(5):1214-20
  • Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia
    Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST
    Leukemia 2015 Apr;29(4):869-876
  • Disseminated tuberculosis associated with ruxolitinib
    Hopman RK, Lawrence SJ, Oh ST
    Leukemia 2014 Aug;28(8):1750-1
  • Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
    Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW
    N Engl J Med 2013 May 9;368(19):1781-90
  • Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
    Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM
    Cancer Res 2013 Jan 1;73(1):285-296
  • A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
    Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J
    Blood 2011 Dec 22;118(26):6988-90
  • LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
    Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A
    Leukemia 2010 Oct;24(10):1713-8
  • Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
    Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J
    Blood 2010 Aug 12;116(6):988-92
  • Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory
    Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL
    J Mol Diagn 2010 Jan;12(1):58-64
  • Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11
    Oh ST, Longworth MS, Laimins LA
    J Virol 2004 Mar;78(5):2620-6
  • Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes
    Thomas JT, Oh ST, Terhune SS, Laimins LA
    J Virol 2001 Aug;75(16):7564-71
  • Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites
    Oh ST, Kyo S, Laimins LA
    J Virol 2001 Jun;75(12):5559-66